BioLizard, a leader in multi-omics integration and AI-powered biopharma analytics, is pleased to announce the appointment of Dr. Alexander Scheer as Chief Scientific Officer (CSO). Dr. Scheer is a highly respected R&D executive with a track record of advancing therapies from discovery to clinical proof-of-concept, bringing over 25 years of leadership across biotech, pharma, and translational research. His appointment marks a significant step in scaling BioLizard’s scientific strategy and impact across biomarker discovery, precision medicine, and AI-driven therapeutic innovation.
